Stock Analysis

Humana Full Year 2024 Earnings: EPS Misses Expectations

NYSE:HUM
Source: Shutterstock

Humana (NYSE:HUM) Full Year 2024 Results

Key Financial Results

  • Revenue: US$117.8b (up 11% from FY 2023).
  • Net income: US$1.21b (down 52% from FY 2023).
  • Profit margin: 1.0% (down from 2.3% in FY 2023).
  • EPS: US$10.01 (down from US$20.09 in FY 2023).
earnings-and-revenue-growth
NYSE:HUM Earnings and Revenue Growth February 12th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Humana EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 28%.

Looking ahead, revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 7.1% growth forecast for the Healthcare industry in the US.

Performance of the American Healthcare industry.

The company's shares are down 13% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Humana has 2 warning signs we think you should be aware of.

Valuation is complex, but we're here to simplify it.

Discover if Humana might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NYSE:HUM

Humana

Provides medical and specialty insurance products in the United States.

Excellent balance sheet, good value and pays a dividend.

Community Narratives

Priced for AI perfection - cracks are emerging
Fair Value US$90.15|47.31% overvalued
ChadWisperer
ChadWisperer
Community Contributor
NVDA Market Outlook
Fair Value US$341.12|61.068999999999996% undervalued
NateF
NateF
Community Contributor
Karoon Energy (ASX:KAR) - Buy Baby Buy 🚀
Fair Value AU$5.10|70.882% undervalued
StockMan
StockMan
Community Contributor